medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2007, Number 3

<< Back Next >>

Rev Mex Urol 2007; 67 (3)

Distribución y estado de maduración de células dendríticas y activación de linfocitos CD4+ en adenocarcinoma prostático

Torres SJJ, Sánchez GDJ, López RMG, Corona PMA

Language: Spanish
References: 18
Page: 140-146
PDF size: 368.00 Kb.


ABSTRACT

Introduction: The cellular immunity plays a very important role in the antitumorlike answer and the dendritic cells are the ones in charge to initiate this answer by means of activation of lymphocytes. The relation is not known that exists between the distribution and state of maturation of dendritic cells and the state of activation of lymphocytes CD4+ in adenocarcinoma prostate.
Objectives: To establish the relation between distribution and mature state of dendritic cells and CD4+ lymphocytes in prostatic adenocarcinoma and benign prostatic hyperplasia (BPH).
Material and methods: We used 20 paraffin embedded prostatic tissues since 2000 until 2002: 15 were prostatic adenocarcinomas and 5 BPH as control group. They were processed by two steps indirect immunohistochemistry, using antibodies against CD1a, DC-SIGN, CD83 and CD4.
Results: There was an increased intratumoral expression of CD1a and DC-SIGN (p‹ 0.001) in the comparison between Gleason 8-9 versus 5-6. There was an increased intratumoral expression of DCSIGN (p‹ 0.01) in the comparison between Gleason 8-9 versus 2-4. An increased intratumoral CD1a and DC-SIGN expression was observed at 8-9 Gleason in comparison with peritumoral areas (p‹ 0.05). There was no expression found with CD83. It was found expression of CD4 in 5 slides.
Conclusions: The CD1a and DC-SIGN expression does not increase progressively in relation of prostatic adenocarcinoma histologic grade. It was demonstrated the co-expression of CD1a and DC-SIGN. There was not observed any relation between dendritic cells and CD4 lymphocytes. It’s not enough to use CD1a and DC-SIGN as unique criteria to identify dendritic cells.


REFERENCES

  1. Herrera GA. Manual de Oncología: Procedimientos Médico-Quirúrgicos 2a ed., Mc Graw-Hill Interamericana, 2003:584-6.

  2. Tanagho EA, McAninch JW. Urología General de Smith. 12ª ed., Manual Moderno, 2001:399-420.

  3. Stites DP, Abba IT, Parslow TG. Inmunología básica y clínica 9ª ed., Manual Moderno, 1998:725-36.

  4. Belz GT, Heath WR, Carbone FR. The role of dendritic cell subsets in selection between tolerance and immunity. Immunol Cell Biol. 2002;80:463-8.

  5. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of Tolerance by IL-10-Treated Dendritic Cells. J Inmunol. 1997;159(10):4772-80.

  6. Pardoll D. T cells and tumors. Nature. 2001;411:1010-2.

  7. Peralta-Zaragoza O, Lagunas M, Madrid V. Factor de crecimiento transformante beta-1: estructura, función y mecanismos de regulación en cáncer. Salud Pública de México. 2001;43:340-50.

  8. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor Specific Immune Responses. J Immunol. 2000;165:3797-803.

  9. Kumamoto T, Huang EK, Paek HJ. Induction of Tumor- specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol. 2002;20(1):64-9.

  10. Ávila MF, Sánchez TC. Alteración en la diferenciación de células dendríticas inmaduras humanas por denocarcinomas pulmonares. Rev Inst Nal Enf Resp Mex. 2002;15:135-142.

  11. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245-52.

  12. Park SH, Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature. 2000;406:788-92.

  13. Levings MK, Sangregorio R, Roncarolo MG. Human CD25 CD4 T Regulatory Cells Suppress Naïve and Memory T Cell Proliferation and Be Expanded In Vitro withut Loss of Function. J Exp Med. 2001;193:1295-1301.

  14. Kazuo Sugamura T. Proteins Reviews CD25. Blood 2002;96:4272-82.

  15. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA et al. Prevalence of Regulatory T Cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-61.

  16. Coventry BJ, Lee PL, Gibbs D, Hart DN. Dendritic cell density and activation status in human breast cancer CD1a, CMRF-44, and CD83 expression. British Journal of Cancer. 2002;86:546-51.

  17. Tjoa BA, Murphy G. Progress in active Specific Immunotherapy of Prostate Cancer. Semin Surg Oncol. 2000;18:80-7.

  18. Boenisch T. Manual de métodos inmunohistoquímicos de coloración. DAKO Corporation, 3ra ed. 2002:20-30.




2020     |     www.medigraphic.com